论文部分内容阅读
目的总结利培酮治疗精神分裂症长期疗效和安全性，寻找适合精神分裂症患者的最佳治疗方案。方法本次研究资料选取2012年2月~2014年9月在本院进行诊治的74例精神分裂症患者，以随机法将其划分成两个小组，即实验组以及对照组。其中，37例对照组研究对象以氨磺必利为主要药物进行治疗，而37例实验组研究对象则以利培酮为主要药物进行治疗，同时对比及分析两组研究对象长期疗效和安全性等基本信息。结果本次研究发现，实验组研究对象在长期疗效和安全性等方面都存在着绝对性优势，比较差异较为显著(<0.05)。结论临床上利培酮治疗精神分裂症长期疗效和安全性较为显著，除了可以有效提升精神分裂症患者长期治疗效率之外，还具有副作用小等临床优势，因此建议推广。“,”Objective To summarize the long-term ef icacy and safety of risperidone treatment of schizophrenic patients, to find the best treatment for schizophrenia patients. Methods This research materials selection in February 2012~September 2014 in our hospital for diagnosis and treatment of 74 cases of schizophrenia patients, in a random method wil be divided into two groups, namely, the experimental group and control group. Of 37 cases of control group research object tolbutamide wil benefit as the main drug treatment, and 37 cases of experimental research object and ketone of culture as the main drug treatment, at the same time, contrast and analysis of two groups of subjects basic information such as long-term ef icacy and safety. Results The study found that the experimental group in such aspects as the research object in the long-term ef icacy and safety of has the absolute advantage, comparative dif erence is significant ( <0.05). Conclusion Clinical long-term ef icacy and safety of risperidone treatment of schizophrenia is significant, in addition to schizophrenic patients long-term treatment can ef ectively improve ef iciency, but also has the clinical advantages of smal side ef ects, it is recommended that promotion.